Citi analyst Joanne Wuensch raised the firm’s price target on Abbott to $125 from $114 and keeps a Buy rating on the shares. Looking into 2023, "many headwinds remain" for the North America medical supplies and technology group, but these should ease in the second half of next year, alleviating operating margin pressures, Wuensch tells investors in a research note. Thus, the analyst is looking for the stocks "that will swim past the pandemic." She does not anticipate it will be an "easy year" to invest in medical technology, but says it "be one of recovery driven by more level-set expectations and product cycles." WWuensch upgraded Glaukos (GKOS) to Buy from Neutral on the stock pull back and ahead of new products, upgraded Becton Dickinson (BDX) to Neutral from Sell on a more reasonable relative valuation, and downgraded Baxter (BAX) to Neutral from Buy, saying "execution is key." She are also upgrading Pulmonx (LUNG) to Buy from Neutral, and opened a "Positive Catalyst Watch" on Silk Road Medic (SILK), saying upside to Q4 and 2023 guidance can continue the stock’s momentum.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ABT:
- Abbott Increases Quarterly Dividend, Marking 51 Consecutive Years of Dividend Growth
- Abbott board increases quarterly dividend 8.5% to 51c per share
- Wolfe Research cuts Edwards Lifesciences to Peer Perform on macro, TAVR maturity
- Abbott put volume heavy and directionally bearish
- Shortages a Boon for These 2 Medical Device Stocks